Explore six key considerations for healthcare professionals regarding Ingrezza (valbenazine), a treatment for tardive dyskinesia. Understand its use, dosing, and safety.

Ingrezza for Healthcare Professionals: Six Key Considerations

For healthcare professionals managing patients with neurological disorders, understanding the available treatment options is crucial. Ingrezza (valbenazine) represents a significant advancement in the treatment of tardive dyskinesia (TD), an involuntary movement disorder. This article outlines six key considerations for healthcare professionals regarding Ingrezza, providing a foundational understanding to inform clinical practice.

1. Understanding Tardive Dyskinesia and Ingrezza's Role

Tardive dyskinesia is a neurological condition characterized by involuntary, repetitive body movements, often affecting the face, mouth, tongue, and limbs. It typically arises as a side effect of long-term use of dopamine receptor blocking agents, such as antipsychotics or certain antiemetics. TD can be debilitating, impacting a patient's quality of life and social functioning. Ingrezza is specifically indicated for the treatment of tardive dyskinesia in adults. Its introduction has provided a targeted therapeutic option for a condition that previously had limited effective treatments, offering clinicians a valuable tool in managing these complex cases.

2. Mechanism of Action: Selective VMAT2 Inhibition

Ingrezza's therapeutic effect stems from its mechanism as a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. VMAT2 is a protein responsible for packaging monoamine neurotransmitters, including dopamine, into synaptic vesicles for subsequent release. By reversibly inhibiting VMAT2, valbenazine reduces the amount of dopamine released into the synaptic cleft. This reduction is thought to decrease the hypersensitivity of dopamine receptors, which is believed to be a contributing factor to the involuntary movements seen in tardive dyskinesia. The selective nature of VMAT2 inhibition is considered important for its therapeutic profile.

3. Indication and Patient Selection

Ingrezza is indicated for the treatment of tardive dyskinesia in adult patients. When considering Ingrezza, healthcare professionals typically assess patients exhibiting persistent, involuntary movements that are characteristic of TD. It is important to differentiate TD from other movement disorders and to confirm that the patient's symptoms are likely related to dopamine receptor blocking agent exposure. Patient selection involves a thorough clinical evaluation, including a detailed medical history, current medication review, and assessment of the severity and impact of dyskinesia on the patient's daily life. Ingrezza is not indicated for pediatric patients or for other movement disorders.

4. Dosing and Administration Guidelines

Ingrezza is available in oral capsule form. The recommended starting dosage for adults is typically 40 mg once daily. After one week, the dosage may be increased to 80 mg once daily, based on patient response and tolerability. A 60 mg once daily dosage is also available for individualization. It is crucial to monitor patients for treatment response and any adverse reactions during titration and maintenance. Dosing adjustments may be necessary in specific patient populations, such as those with hepatic impairment or those concurrently taking strong CYP2D6 inhibitors. Ingrezza can be taken with or without food.

5. Important Safety Information and Adverse Reactions

Healthcare professionals should be aware of important safety information associated with Ingrezza. Warnings include QT prolongation, which necessitates careful consideration in patients with known QT prolongation, arrhythmias, or concurrent use of other QT-prolonging drugs. Somnolence and sedation are common side effects, and patients should be advised of potential impaired ability to perform hazardous tasks. Other reported adverse reactions include anticholinergic effects, Parkinsonism, and akathisia. It is important to counsel patients on potential side effects and to regularly monitor for these and other adverse events throughout treatment. Sudden discontinuation is generally not recommended.

6. Special Populations and Drug Interactions

Considerations for special populations include patients with hepatic impairment, where dosage adjustments are typically recommended. For severe hepatic impairment, the maximum recommended dosage is 40 mg once daily. Renal impairment does not generally require dosage adjustment. Ingrezza is metabolized by CYP3A4 and CYP2D6 enzymes. Concurrent use of strong CYP3A4 inhibitors (e.g., ketoconazole) may require a dosage reduction of Ingrezza, while strong CYP3A4 inducers (e.g., rifampin) may reduce Ingrezza exposure, potentially decreasing its efficacy. Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine) may necessitate an Ingrezza dosage reduction to 40 mg once daily. A comprehensive review of a patient's current medication list is essential to identify potential drug interactions.

Summary

Ingrezza (valbenazine) offers healthcare professionals a targeted treatment option for adults living with tardive dyskinesia. Understanding its mechanism of action as a selective VMAT2 inhibitor, appropriate patient selection, recommended dosing schedules, potential safety considerations, and drug interaction profiles are paramount for effective and safe patient management. By integrating these key considerations into their clinical practice, healthcare professionals can optimize outcomes for patients experiencing the challenging symptoms of tardive dyskinesia.